- Home
- EBON vs SCYX Comparison
EBON vs SCYX Comparison
Compare EBON & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EBON | SCYX |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4M | 24.6M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EBON | SCYX |
|---|---|---|
| Price | $3.89 | $0.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 4.9K | ★ 506.3K |
| Earning Date | 08-15-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,337,066.00 | $2,932,000.00 |
| Revenue This Year | N/A | $167.73 |
| Revenue Next Year | N/A | $290.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 104.28 | N/A |
| 52 Week Low | $3.00 | $0.57 |
| 52 Week High | $8.54 | $1.49 |
Technical Indicators
Market Signals| Indicator | EBON | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 44.02 |
| Support Level | $3.37 | $0.63 |
| Resistance Level | $3.89 | $0.67 |
| Average True Range (ATR) | 0.18 | 0.03 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 26.92 | 13.89 |
Price Performance
Historical ComparisonAbout EBON Ebang International Holdings Inc.
Ebang International Holdings Inc is a blockchain technology and Fintech company, that has ASIC chip design capability. Its business is ASIC chip design and Telecommunication. It operates in a single segment selling bitcoin mining machines and related accessories, telecommunication products, providing cryptocurrency exchange services, management and maintenance services, and cross-border payment and foreign exchange services and rental services. Its geographic regions are Mainland China, and Australia.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.